Home › News › Clinical Trials › Archive

Clinical Trial News Archive

Get news By email or subscribe to our News feeds.

All News Consumer Pharma New Drugs Pipeline Clinical Trials

September 2008

September 2

Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008 Cyclacel Announces Recommendations of Data Review Committee for Seliciclib Phase 2b Non-Small Cell Lung Cancer APPRAISE Trial Fibrex Medical Report Positive Phase II Results for FX06 Erbitux Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated With Second-Generation TAXUS Liberte Stent Volcano's VH IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib Presentations on the Mechanism of Action of VEGFb, the World's Only "Angiogenesis Modulator," Support VEGFb's Role as an Epical Treatment for Solid Cancers, Macular Degeneration, and Other Diseases New Data is Presented on Investigational Oral Anticoagulant Apixaban in Acute Coronary Syndrome Patients Targanta Therapeutics Announces Positive Top-Line Results from Oritavancin Phase 2 SIMPLIFI Trial Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue SCAI: CARDia Data Find Diabetic Patients With Complex Heart Disease Can Safely Choose PCI Post-Marketing Studies Finding Adverse Events in Drugs Used in Children SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First 'Real World, All Comers' Clinical Study Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation Lipitor 80 mg Provided Sustained Risk Reduction of Cardiovascular Events in Patients with Heart Disease During the Five-Year TNT Trial American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast Pronova BioPharma ASA Announces Significant Clinical Data presented at ESC: OMACOR Reduces Mortality and Hospitalisations in Patients with Congestive Heart Failure Cosmo Successfully Completes the First Phase I Clinical Trial of its Anti-Androgen, CB-03-01, for the Treatment of Skin Disorders n-3 PUFAs Reduce Mortality and Hospital Admissions in Patients With Symptomatic Heart Failure With the BEAUTIFUL Results, Procoralan (ivabradine) is the First Antianginal Treatment Shown to Reduce Myocardial Infarction (Heart Attack) and Revascularisation in Stable Coronary Patients Presentations on the Mechanism of Action of VEGFb, the World's only "Triple Action Angiogenesis Modulator," Support VEGFb's Role as a Promising Treatment for Solid Cancers, Macular Degeneration, and Other Diseases Anavex Completes Successful Preclinical Studies on Lead Alzheimer's Drug Candidate ApoA-I Data Presented at European Society of Cardiology Congress Theratechnologies Announces Publication in AIDS MorphoSys Announces Publication of First MOR103 Data Prominent Psychiatrist Challenges Placebo Response in Depression

September 3

Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel LUNESTA Next-Day Function and Discontinuation Data from a Long-Term 12-Week Study in Elderly Patients Presented at ECNP Phase III U.S. Pivotal Study Results on CSL Biotherapies' Afluria Published in Vaccine Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch Alexza's AZ-004 (Staccato Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients Further Analysis From Athena Study Showed That Multaq (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation Intercell AG Announces Favourable Six Months Follow-Up Results from HCV Vaccine Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis Rasilez , First-in-Class Direct Renin Inhibitor, Lowers High Blood Pressure More Effectively Than Diuretic in Obese Patients Regeneron's ARCALYST (rilonacept) Reduced Incidence of Gout Flares by 81 Percent in a Phase 2 Study in Gout Patients Initiating Urate-Lowering Therapy Regeneron Announces Webcast Presentation of Results from Phase 2 Study of Arcalyst (rilonacept) in Gout Patients Initiating Urate-Lowering Therapy Somaxon Presents Pharmacological Data on Doxepin at the 21st European College of Neuropsychopharmacology Congress Adagio trial results show Teva's Azilect 1 mg tablets slow progres... Lunesta Next-Day Function and Discontinuation Data from a Long-Term 12-Week Study in Elderly Patients Presented at ECNP Medicure Inc.: New Data Shows Aggrastat Offers Significant Benefits to Patients with Poor Response to Aspirin and/or Clopidogrel New Analysis From HORIZONS-AMI Shows Major Bleeding Has a Significant Impact and Contributes to 30-Day Mortality Following Angioplasty in Severe Heart Attack Patients Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program

September 5

Inhibiton Therapeutics' Researcher to Present at the Ehrlich II, 2ND World Conference on "Magic Bullets" Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Data Indicate that Percutaneous Coronary Intervention with the Cypher Sirolimus-eluting Coronary Stent Is Comparable to Bypass Surgery Immigrants From India, Pakistan Face U.S. Prostate, Breast Cancer Risks NovaDel Announces Data from Pilot Efficacy Study Comparing Sumatriptan Oral Spray to Imitrex Tablets NeurAxon's NXN-188 Demonstrates Pain Relief in Migraine with Aura A New Potential Path to Curing Inflammatory Bowel Diseases Emerges through Gene Research Funded by the Crohn's & Colitis Foundation of America 338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis ProtAffin AG Granted Orphan Drug Designation in the US for Lead Anti-inflammatory Product The Cancer Genome Atlas Reports First Results of Comprehensive Study of Brain Tumors M. D. Anderson Study Finds Change in HER2 Status After Treatment With Herceptin Sarah Cannon Research Institute Presents New Findings in Breast Cancer Treatment Creating Lung Cancer Risk Models For Specific Populations Refines Prediction

September 8

Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 Onglyza (saxagliptin) Demonstrated Significant Improvements Across Key Measures of Glucose Control When Added to a Sulfonylurea or Thiazolidinedione in People With Inadequately Controlled Type 2 Diabetes iCardiac Completes Industry's Largest Validation Study of Highly Automated QT Analysis Columbia Laboratories to Release Top Line Results of Phase II Lidocaine Study in Late September XOMA 052 Clinical Results Support New Type 2 Diabetes Therapeutic Approach of Targeting Inflammatory Damage to Insulin-Producing Cells Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008 Biodel Announces Preliminary Results of Pivotal Phase III Clinical Trials for VIAject BioSante Pharmaceuticals Announces Positive Oral Contraceptive Clinical Results New Data on Breast Imaging Using Cardiolite to Be Presented at ASCO Breast Cancer Symposium 2-Day Ovarian Cancer Symposium Closes with a Promise to Find a Cure Epigenomics Reports Positive Interim Results in Prostate Cancer Clinical Study Saxagliptin Improved Key Measures of Glucose Control When Added to a Sulphonylurea or Thiazolidinedione in People with Inadequately Controlled Type 2 Diabetes 'Black Sheep Protein' Key to Cancer Cell Death Tekmira Pharmaceuticals Collaborator National Cancer Institute Presents Anti-Tumor Data at Liver Cancer Conference Biocon Limited Presents Human Clinical Data on IN-105 (oral insulin) at the EASD Meeting in Rome Pro-Pharmaceuticals Submits Data with FDA to Support IND Targeting Resistance to Chemotherapy Due to Hypoxia New Advance Findings Show How to Combine Intensive Blood Glucose and Blood Pressure Lowering for Further Benefits in Type 2 Diabetes Protein “Switch” Suppresses Skin Cancer Development When IKKalpha fails to Keep Cell Replacement Cycle in Balance, Cancer Follows

September 9

First Reported Head-to-Head Study Showed Byetta (exenatide) Injection Provided Greater Reduction in Post-Meal Glucose Levels Than Januvia (sitagliptin) in Patients With Type 2 Diabetes Onglyza (saxagliptin) With Metformin as Initial Combination Therapy Significantly Lowered A1C and Demonstrated Significant Improvements Across Key Measures of Glucose Control in Treatment Naive People With Type 2 Diabetes Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting Data to Be Presented At ESMO 2008 Highlight Pfizer Commitment to Cancer Care and Research Hospitals Participating in Get With The Guidelines Program Follow Heart Attack Treatment Guidelines Better Than Others Encouraging Gene Therapy Results in Genetic Form of Blindness Five New Studies at Major Medical Meeting Further Demonstrate Clinical Experience for Januvia (sitagliptin) Oxford BioMedica Announces Promising Interim Phase I/II Results of Prosavin in Parkinson's Disease MediGene Announces New Clinical Data for EndoTAG-1 to be Presented at ESMO Conference Data Show Galvus Better Tolerated by Patients with type 2 Diabetes, with no Weight Gain, a Favorable Cardiovascular Profile and Equal Efficacy Compared to Widely-used TZDs Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting

September 10

GTx to Present Additional Efficacy and Safety Analyses from the Toremifene 80 mg Phase III ADT Clinical Trial at the Annual Meeting of the American Society for Bone and Mineral Research Circassia Achieves Successful Phase II Clinical Results With Toleromune Anti-Allergy Technology Pluristem Successfully Concludes Final Pre-Clinical Safety Studies with PLX-PAD in Preparation for Human Trials National Survey Reveals Contradictory Awareness Levels of High Cholesterol and Atherosclerosis Among Hispanic Americans Newly Released Data on Onset of Effect and Patient Perception With Symbicort in Adults With Asthma PainCeptor Pharma Announces Positive Clinical Results that Validate ASICs as Novel Targets for Human Pain Cryo-Cell to Present Cutting-Edge Stem Cell Research at Global Regenerative Science Conferences New in Vitro Toxicology Application for DRAQ5 Lux Biosciences' Investigational Therapy for Uveitis, Luveniq, to be Featured at 7th International Symposium on Uveitis Addex: Better Tolerated Formulation of ADX10059 Reduces Acid Reflux Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With Lantus and Apidra to Improve Blood Sugar Control in Patients With Type 2 Diabetes New Phase II Data Show Novartis Investigational Meningitis B Vaccine May Also Protect Infants Six Months and Older Sciele Pharma and Addrenex Pharmaceuticals Announce Positive Phase III Clinical Results of Clonicel for ADHD

September 11

Long-Term Phase I and Phase I/II Trial Data Continue to Show Striking Improvement in Survival of Brain Cancer Patients Who Receive DCVax-Brain MannKind Corporation to Host Webcast Analyst Day September 16, 2008 Instituto de Medicina Molecular, Cenix BioScience, and Alnylam Pharmaceuticals Discover New Pathway for Malaria Infection Cerimon Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain Study Published in NEJM Shows Erbitux Improved Survival in First-Line Recurrent And/Or Metastatic Head and Neck Cancer Top-Line Data from Opexa's Phase IIb Tovaxin Study to be Presented at World Congress on Treatment and Research in MS Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD Levemir Demonstrates a 24-hour Duration of Action and Significant Weight Loss in Obese Patients – New Studies Announced Accelr8 Announces Publication of New Study on its OptiChem High-Performance Bio-Coatings The International Myeloma Foundation Says Journal Editorial Documents Dramatic Increase in Survival since the 1980's Study Published in New England Journal of Medicine Shows ERBITUX Improved Survival in First-Line Recurrent And/Or Metastatic Head and Neck Cancer VAI Findings Could Aid Diagnosis and Treatment of Several Types of Kidney Cancer Allergan Announces Positive Top-Line Results from Phase III BOTOX Headache Program Presentation of Immune Response Data to Intratumoural Injections of CAVATAK in Late Stage Melanoma Patients Zosano Pharma, Inc. Announces Positive Results of Phase 2 Trial With PTH Transdermal Patch in Osteoporosis Amgen to Present Important Clinical Trial Data at Two Key Congresses Amgen to Present Important Clinical Trial Data at Two Key Congresses Clinical Trial Investigators to Present New Data Next Week on Nymox's NX-1207 For Benign Prostatic Hyperplasia One-In-Three Multiple Sclerosis Patients Admit They Don’t Like Injecting Their Medication Due to Discomfort, Survey Reveals Interesting New Data on the Effect of Candesartan on Diabetic Eye Complications Herpes Virus Changes Anti-herpes Drug to Form that Hinders AIDS Virus Allergan Announces Positive Top-Line Results from Phase III Botox Headache Program Novel Compound Shows Promise for Treatment of Alcoholism

September 15

Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy Pluristem Therapeutics to Present at the bioLOGIC Conference Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect Global Study Shows That Majority of Women with Osteoporosis Do Not Consider Themselves at Higher Risk for Fractures Inovio Biomedical Achieves 75% Complete Response Rate in Preclinical Testing of DNA-Based Cancer Vaccine Using Its Electroporation DNA Delivery System Bionovo's MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes Promising Clinical Phase I results for Intravenous CP-4126 presented at ESMO Positive Interim Data from Phase 2 Study of NPSP558 (Parathyroid Hormone 1-84) for Hypoparathyroidism Reported at ASBMR Annual Meeting Transgene's Therapeutic Vaccine TG4010: Promising Additional Clinical Data in Non-Small Cell Lung Cancer Phase IIb Trial VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008 Teva to Present New Treatment Data at World Congress for Multiple Sclerosis Pfizer Oncology Presents Safety and Efficacy Results Of CP-751,871 Study At ESMO 2008 Updated Survival Data from Three Phase 2 Ipilimumab Studies Showed Almost Half of Previously Treated Metastatic Melanoma Patients Alive Beyond One Year DNA Vaccine Developed at the Karmanos Cancer Institute Fights HER2-Positive Cancers Sangamo BioSciences Announces Presentation of Data From Diabetic Neuropathy Clinical Trials Elesclomol Two-Year Survival and Integrated Safety Data Presented at the 33rd Congress of the European Society for Medical Oncology What is the Optimal Method of Ischemia Evaluation in WomeN: Preliminary Data from the WOMEN Study RAD001 Combined with Sandostatin LAR Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors Tyverb Demonstrates Encouraging Results in Phase II Study in Advanced Head and Neck Cancer Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice Epeius Biotechnologies' Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal Denosumab Osteoporosis Trial Finds Patients Transitioned from Alendronate (Fosamax) to Denosumab Achieved Greater Gains AVAiL study shows longest survival in patients with advanced non-small cell lung cancer DOR BioPharma Announces Second orBec Clinical Summary Published in "Expert Opinion on Investigational Drugs" Canakinumab (ACZ885), a new biological drug in development, shows potential in treating the most severe form of arthritis in children Merck KGaA: Erbitux – First treatment in 30 Years to Prolong Survival in 1st-Line Recurrent and/or Metastatic Head and Neck Cancer Study Provides Clues About How Cancer Cells Develop Resistance to Chemotherapy Drug Most Cancer Treatment Studies Aren't Published, Study Finds Thallion Presents Final Phase II TLN-232 Results in Advanced Kidney Cancer Patients at the ESMO Congress Trastuzumab Improves the Efficacy of Chemotherapy in Breast Cancer Treatment Beyond Progression

September 16

AstraZeneca and Targacept Announce Top-Line Results from Phase 2b Study of AZD3480 in Alzheimer's Disease Targacept to Host Conference Call Today at 5:15 p.m. to Discuss Phase 2b Results for AZD3480 in Alzheimer's Disease ImClone Provides Update on Pivotal Phase 3 CRYSTAL Study in First-Line Metastatic Colorectal Cancer Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes Valeant Announces Presentation of Retigabine Data at the 8th European Congress on Epileptology Pluristem Presents Final PLX-PAD Efficacy Data Supporting Upcoming IND Submission to the U.S. FDA Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting Interface Biologics' Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations Modified Insulin Most Effective For Controlling Post-Meal Blood Sugar Levels MediGene Reports Positive 12-Month Survival Data for EndoTAG-1 from Phase II Pancreatic Cancer Study InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies Sciele Completes Pivotal Phase III Program for Glycopyrrolate in Pediatric Patients with Chronic, Moderate-to-Severe Drooling Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntington's Disease Model Clinical Trial Results for NX-1207 to be Presented at Second AUA Meeting in San Diego on September 18 New Data Confirms Avastin as the Only Biologic to Demonstrate Overall Survival When Used First-Line in Metastatic Colorectal Cancer Patients With K-RAS (Wild-Type) Gene Status GTx Presents Bone Turnover Marker Data and Additional PSA Progression Safety Analysis for Toremifene 80 mg Phase III ADT Clinical Trial Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Increased BMD Over Two Years at Key Fracture Sites in Phase IIB Study Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis New Bisphenol A Study Has Limited Capability to Assess Human Health Effects

September 18

Continuous Treatment With Abbott's Humira Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment Incyte's Topical JAK Inhibitor Demonstrates Positive Proof-of-Concept Results in Patients with Mild to Moderate Psoriasis Landmark Study Shows Ustekinumab Demonstrated Superior Efficacy to Enbrel (Etanercept) for Moderate to Severe Plaque Psoriasis MicroRNA First Disclosed by Rosetta Genomics May Increase Efficacy of Imatinib (Gleevec) in Glioblastoma Biogen Idec Features Data on Avonex and Tysabri and Showcases the Company's Multiple Sclerosis Development Pipeline at the World Congress On Treatment and Research in Multiple Sclerosis Preliminary Data from Experimental Study Demonstrate Increased Mortality in Stroke Patients Treated With Epoetin Alfa New Gene Therapy Offers Hope for Duchenne Muscular Dystrophy Patients PharmAthene to Present Data for Protexia and Valortim at HHS PHEMCE Stakeholders Workshop 2008 Longest Prospective Study in MS Confirmed Robust Clinical Benefits and Safety of Copaxone New Long-Term Data Show That Patients Taking Avonex for up to 15 Years Experience Reduced Disability Progression and Improved Quality of Life Scientific Abstracts On Cystinosis Research Are Published In October Issue of Pediatric Nephrology Laquinimod Demonstrated Significant and Sustained Impact on Multiple Sclerosis Disease Activity

September 19

Sucampo Pharmaceuticals Announces Positive Results from a Japanese Phase 2b Dose-Ranging Study of AMITIZA(R) for Chronic Idiopathic Constipation Novartis MF59-Adjuvanted Vaccine Rapidly Induces Protective Antibody Levels Against Diverse Strains of Avian Flu Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy Nymox NX-1207 Data Presented at American Urological Association Meetings in San Diego and Santa Ana Pueblo, New Mexico Monitoring Exhaled Nitric Oxide Does Not Help Manage Asthma New Data Presented at WCTRIMS Supports the Importance of Early and Sustained Treatment with Betaseron Opexa Announces Top-Line Results from Phase IIb Clinical Trial of Tovaxin for the Treatment of Multiple Sclerosis Tysabri Demonstrates Sustained Improvement in Functional Outcomes in Multiple Sclerosis Patients According to New Post-Hoc Analysis Copaxone Demonstrated Protective Effect in Patients with Clinically Isolated Syndrome Suggestive of Multiple Sclerosis

September 22

Acorda Therapeutics Presents Additional Data from Second Positive Phase 3 Study of Fampridine-SR at World Congress on Treatment and Research in Multiple Sclerosis ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis Pivotal Phase III Pollinex Quattro Ragweed Study Meets Primary Efficacy Derma Sciences' Medihoney Abstract Available Online Five-Year Data Confirm That Early Treatment with Betaseron at First Sign of Disease Can Delay Progression to MS Merck KGaA: Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif at 16 Weeks in Patients with Multiple Sclerosis Longest prosPective study in ms confirmed Robust clinical benefits and safety of Copaxone Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes Biopartners presents three year safety and efficacy data for sustained release recombinant human growth hormone (LB03002) at ESPE 2008 New Hope for the Sad Heart: SADHART Clinical Trial Presents Evidence of How Treatment Can Improve Depression and Morbidity in Heart Failure Napo Announces Positive Clinical Data Indicating Crofelemer, Could Effectively Treat Cholera Erbitux Five-Year Data Show Significant Improvement in Overall Survival for Patients with Locally or Regionally Advanced Head and Neck Cancer

September 23

Off-label Medicine Combinations are Predominant Treatment of Schizophrenics According to PLoS Article Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canada's Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX in Preventing Blindness in Premature Infants Opexa Announces Top-Line Results from Phase IIb Clinical Trial of Tovaxin for the Treatment of Multiple Sclerosis Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America Sub-Analysis of Phase III Suggests Long-Term Therapy May Improve Physical and Social Functioning In CIDP Patients Use of Proven Heart Failure Therapies Not Standardized in the United States Sub-Analysis of Phase III Study Suggests More than Single Treatment may be Required for Therapeutic Response in Some Patients with CIDP Half of Trials Supporting FDA Applications Go Unpublished Clinical Results for Nymox BPH Drug NX-1207 to Be Presented at American Urological Association Meeting in Chicago on September 25

September 24

Telaprevir Presentations at the 59th AASLD Meeting to Feature SVR Data in Treatment-Naive and Treatment-Failure Genotype 1 HCV Patients, and Clinical Data Exploring Twice-Daily Dosing Regimens Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference Medications Commonly Prescribed for COPD Associated With Increased Risk of Cardiovascular Death, Heart Attack or Stroke GATTEX Abstracts to be Presented at ACG Meeting; 52-Week Data from Phase 3 Clinical Trial Scheduled for Plenary Session Established Safety Profile of Spiriva Confirmed by 30 Rigorously Controlled Clinical Trials and the Landmark Trial UPLIFT InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting PharmAthene Presents Data for Protexia and Valortim at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy Isotechnika Selected to Present at International Transplantation Conference Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients Phase IIa Data on TMC435350 in Patients with Hepatitis C to be Presented at AASLD Vertex Pharmaceuticals Announces Correction to Abstract Data Published in October 2008 Supplement to Hepatology Joint Commission Alert: Prevent Blood Thinner Deaths and Overdoses New Data Show Efficacy of Zebinix in the Treatment of Epilepsy Early-Stage Breast Cancer Patients Who Receive Neoadjuvant Therapy Followed by Mastectomy May Not Need Radiation GlobeImmune Announces Late-Breaker Presentation of Interim Efficacy and Safety Data for GI-5005 at AASLD 2008 Meeting New Data Show Efficacy and Safety of Eslicarbazepine Acetate in the Treatment of Epilepsy

September 25

Hollis-Eden Pharmaceuticals Presents Positive Updated Data from Phase I/II Clinical Trial with TRIOLEX in Obese Insulin Resistant Subjects Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex in Current International Phase 3 Trials Array BioPharma Presents Positive Preclinical Data on Its Glucokinase Activators in Type 2 Diabetes Concert Pharmaceuticals Presents Preclinical Results Supporting Co-Administration of CTP-347 and Tamoxifen Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet Ready and Willing, but Unable? Survey Reveals Boomers Desire Sex, But Face Physical Challenges New Data Show Efficacy and Safety of Eslicarbazepine Acetate in the Treatment of Epilepsy invivodata Captures Symptom Relief Data in Endometriosis Trial CytRx Corporation to Present New Data from Its Proprietary Molecular Chaperone Drug Discovery Technology at the San Diego LEADS Meeting Retrospective Analysis of Phase 3 Data Suggest Wyeth's Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms Data from One-year Liraglutide Phase 3 Study Published in The Lancet Nymox NX-1207 Data Presented Today at American Urological Association Meeting in Chicago Publication in European Heart Journal Highlights Potential of Santhera's SNT-MC17/idebenone in Duchenne Muscular Dystrophy

September 29

ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin Watson Announces Positive Data for RAPAFLO(silodosin), Its Investigational Product for BPH, at Regional AUA Conferences VGX Pharmaceuticals Commences Follow-on Phase I Study for Novel Oral Anti-Inflammatory Drug Targeting Rheumatoid Arthritis and Type 1 Diabetes Hollis-Eden Pharmaceuticals Presents Additional Positive Findings for APOPTONE (HE3235) in Preclinical Models of Castration-Resistant Prostate Cancer Columbia Laboratories Reports Results from Phase II Clinical Trial of Vaginally-administered Lidocaine for Dysmenorrhea PolyMedix Presents Data on Anti-Tuberculosis Activity of its Novel Antibiotic Compounds Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4 VEGF Trap-Eye Final Phase 2 Results in Age-related Macular Degeneration Presented at 2008 Retina Society Meeting

Clinical Trial Results Archive

2005

April

More News Resources

(web5)